United States Premenstrual Syndrome Treatment Market Size and Forecast 2025–2033

The United States Premenstrual Syndrome (PMS) Treatment Market is projected to grow steadily from US$ 517.31 Million in 2024 to US$ 730.58 Million by 2033, expanding at a compound annual growth rate (CAGR) of 3.91% from 2025 to 2033. Increasing awareness of PMS, improved diagnostic practices, and advancements in both pharmacological and non-pharmacological treatment options are driving demand across the country.

As conversations around women’s health become more open and data-driven, PMS is no longer viewed as a minor inconvenience but as a condition requiring structured medical attention. This shift in perception is strengthening market growth and encouraging healthcare providers and pharmaceutical companies to expand targeted solutions.

United States Premenstrual Syndrome Treatment Market Outlook

Premenstrual Syndrome affects a large percentage of menstruating individuals during their reproductive years. Symptoms—ranging from mood swings and irritability to bloating, headaches, fatigue, and cramps—typically occur during the luteal phase of the menstrual cycle.

Treatment approaches vary widely and include:

·        Lifestyle modifications such as exercise and dietary management

·        Over-the-counter (OTC) pain relievers

·        Antidepressants (especially SSRIs)

·        Hormonal therapies and oral contraceptives

·        Nutraceutical supplements

In the U.S., growing recognition of PMS as a clinically manageable condition has reduced stigma and encouraged women to seek professional care. Online health communities, telehealth services, and digital symptom-tracking platforms further enhance awareness and access to treatment.

According to the Office on Women’s Health, more than 90% of women experience premenstrual symptoms at some point during their reproductive years—highlighting the significant addressable patient base.

Download Free Sample Report:https://www.renub.com/request-sample-page.php?gturl=united-states-pms-treatment-market-p.php

Growth Drivers in the U.S. PMS Treatment Market

Rising Awareness and Improved Diagnosis

Increased awareness campaigns led by healthcare organizations and women’s wellness brands have improved early diagnosis and symptom recognition. Social media discussions and telehealth consultations are empowering women to seek medical support rather than self-manage symptoms indefinitely.

As mood-related symptoms gain recognition alongside physical discomfort, healthcare providers are more likely to prescribe targeted treatments such as SSRIs, hormonal therapies, or combination regimens. Workplace wellness programs have also begun addressing hormonal health, further legitimizing PMS as a medical concern.

Expansion of Women’s Healthcare Infrastructure

The expansion of gynecology clinics, hormonal health centers, and integrated women’s wellness facilities is significantly improving access to PMS care.

Telemedicine platforms have reduced barriers to consultation, enabling remote prescriptions and follow-up visits. Insurance coverage for reproductive and mental health services has also improved affordability.

In February 2025, Opill® launched a multi-state college tour and expanded its WNBA partnership under the “Level The Court” initiative to enhance reproductive health awareness and accessibility—demonstrating growing institutional support for women’s hormonal health initiatives.

Increasing Demand for Non-Hormonal and Natural Therapies

A major market trend is the shift toward natural and non-hormonal treatments. Many women prefer herbal supplements, vitamins, and lifestyle-based approaches to minimize side effects.

Popular options include:

·        Calcium and magnesium supplements

·        Vitamin B6

·        Chasteberry

·        Evening primrose oil

·        Stress management programs and yoga

In January 2025, the FDA approved Journavx (suzetrigine), a non-opioid oral analgesic developed by Vertex Pharmaceuticals for moderate to severe acute pain. Though not exclusively for PMS, such innovations may expand pain-management options relevant to menstrual health.

The increasing demand for plant-based and clean-label products is encouraging pharmaceutical and nutraceutical companies to diversify offerings within this segment.

Key Market Challenges

Lack of Standardized Diagnostic Criteria

One of the primary barriers to optimal market growth is inconsistent diagnosis. PMS symptoms overlap with conditions such as anxiety disorders and thyroid dysfunction, leading to underdiagnosis or misclassification.

Many women continue to self-medicate with OTC solutions without clinical evaluation. Variability in diagnostic approaches among providers further complicates treatment consistency.

Addressing these gaps requires standardized screening tools, expanded education campaigns, and broader access to gynecological care—particularly in underserved communities.

Side Effects and Limited Drug Efficacy

While SSRIs and hormonal therapies are widely prescribed, they can produce side effects such as nausea, sleep disturbances, weight changes, and sexual dysfunction.

Variability in patient response often leads to treatment discontinuation. Pharmaceutical innovation must focus on developing safer, better-tolerated formulations, including extended-release and multi-symptom therapies to improve adherence.

Segment Insights

Analgesics Segment

The U.S. analgesics PMS treatment market remains vital for addressing physical symptoms such as cramps, headaches, and muscle pain.

Nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen and naproxen are widely used due to:

·        Fast action

·        Broad availability

·        Affordability

Pharmaceutical companies are developing improved gastrointestinal-tolerant and extended-release formulations. Increased focus on self-care is expected to sustain growth in this segment.

Antidepressants Segment

Antidepressants—particularly selective serotonin reuptake inhibitors (SSRIs)—are commonly prescribed for severe PMS and Premenstrual Dysphoric Disorder (PMDD).

Greater recognition of mood-related symptoms has positioned SSRIs as first-line therapy in many cases. Telepsychiatry and online prescription services further facilitate access.

However, managing side effects and ensuring compliance remains critical for sustained segment expansion.

Prescription PMS Treatment Market

Prescription therapies, including hormonal contraceptives and antidepressants, are gaining momentum due to improved diagnostic awareness and expanded telehealth services.

Combination drug formulations targeting multiple symptoms simultaneously are emerging as convenient solutions. Insurance coverage further enhances affordability and compliance.

As integration between mental health and reproductive health services strengthens, prescription-based PMS treatment is expected to maintain steady growth.

Distribution Channels

Hospital Pharmacies

Hospital pharmacies play a significant role in dispensing advanced and prescription-grade PMS medications. Integrated care models—where gynecologists collaborate with psychiatrists and nutritionists—improve treatment outcomes.

Expansion of hospital-based women’s health departments further supports this segment.

Online Stores

The online PMS treatment market is rapidly expanding due to e-commerce growth and telehealth integration.

Key advantages include:

·        Privacy

·        Subscription refills

·        Competitive pricing

·        Digital symptom-tracking integration

Although counterfeit risks and regulatory oversight remain concerns, licensed online pharmacies continue gaining consumer trust.

Regional Insights

California

California leads regional growth due to strong healthcare infrastructure, wellness culture, and digital health adoption. Cities like Los Angeles and San Francisco offer extensive gynecological and integrative wellness services.

The state’s openness to holistic therapies supports demand for both prescription and natural PMS solutions.

New Jersey

Proximity to pharmaceutical hubs enhances innovation and availability of advanced PMS treatments. Strong insurance coverage and healthcare access contribute to consistent growth.

Washington

Washington’s focus on preventive healthcare and telemedicine adoption fosters growth in both traditional and holistic PMS treatment solutions. Partnerships between digital health providers and clinics improve patient engagement and adherence.

Competitive Landscape

Leading companies operating in the U.S. PMS treatment market include:

·        AbbVie Inc.

·        BASF SE

·        Bayer AG

·        Dr. Reddy’s Laboratories Ltd

·        Eli Lilly and Company

·        GlaxoSmithKline Plc.

·        H. Lundbeck A/S

·        Pfizer Inc.

·        SHIONOGI & Co. Ltd.

Each company is evaluated across five viewpoints: Overview, Key Personnel, Recent Developments, SWOT Analysis, and Revenue Analysis.

Market Segmentation

By Drug Type:
Analgesics
Antidepressants
Oral Contraceptives and Ovarian Suppression Agents
Others

By Type:
Prescription
Over-the-Counter

By Distribution Channel:
Hospital Pharmacies
Drug Stores and Retail Pharmacies
Online Stores

By Top States:
California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio, Georgia, New Jersey, Washington, and others.

Final Thoughts

The United States PMS Treatment Market is projected to grow steadily from US$ 517.31 Million in 2024 to US$ 730.58 Million by 2033, reflecting sustained demand for improved women’s healthcare solutions.

Rising awareness, digital health adoption, and product innovation are strengthening market momentum. While diagnostic inconsistencies and medication side effects present challenges, advancements in safer formulations and holistic therapies offer promising opportunities.

As societal dialogue around hormonal health continues to evolve, PMS treatment is becoming an integrated component of comprehensive women’s healthcare—positioning the market for stable and meaningful long-term growth.